SCHEMBL1242989

SCHEMBL1242989

Cc1c(C)c(O)c(-c2c(O)c(C)c(C)c(C)c2C(C)C)c(C(C)C)c1C

nearest known ligand 0.35

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
BCL2 P10415 3/20 0.35
MCL1 Q07820 3/20 0.35
BCL2L1 Q07817 2/20 0.35
BCL2L2 Q92843 2/20 0.35
GABRA1 P14867 1/20 0.31
GABRB1 P18505 1/20 0.31
ALB P02768 2/20 0.31
LDHA P00338 2/20 0.31
LDHB P07195 2/20 0.31
KDM4E B2RXH2 1/20 0.30
MEN1 O00255 1/20 0.30
NPC1 O15118 1/20 0.30
USP2 O75604 1/20 0.30
ALDH1A1 P00352 1/20 0.30
LMNA P02545 1/20 0.30
ESR1 P03372 1/20 0.30
TP53 P04637 1/20 0.30
CYP1A2 P05177 1/20 0.30
POLB P06746 1/20 0.30
CYP3A4 P08684 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19972877 0.83 BCL2 (0.33) BCL2MCL1BCL2L1BCL2L2GABRA1
SCHEMBL19183569 0.81 BCL2 (0.32) BCL2MCL1BCL2L1BCL2L2LDHA
SCHEMBL9070220 0.80 BCL2 (0.34) BCL2MCL1BCL2L1BCL2L2GABRA1
SCHEMBL23943247 0.76 LDHA (0.35) BCL2MCL1BCL2L1BCL2L2ALB
SCHEMBL14201680 0.76 LDHA (0.35) BCL2MCL1BCL2L1BCL2L2ALB
SCHEMBL8330118 0.73
SCHEMBL11653101 0.72 BCL2 (0.38) BCL2MCL1BCL2L1BCL2L2GABRA1
SCHEMBL992964 0.70 SENP1 (0.39)
SCHEMBL5526052 0.69 BCL2 (0.34) BCL2MCL1BCL2L1BCL2L2GABRA1
SCHEMBL31146654 0.69

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1467958-B1 PROCESS FOR PREPARING 3,3',5,5',6,6'-HEXAALKYL-2,2'-BIPHENOLS, 3,3',4,4',5,5'-HEXAALKYL-2,2'-BIPHENOLS AND 3,3',4,4',5,5',6,6'-OCTAALKYL-2,2'-BIPHENOLS INVISTA TECH SARL (CH) 2014-01-08 EP disclosed
EP-2279993-A1 Process for preparing 3,3',5,5',6,6'-hexaalkyl-2,2'-biphenols, 3,3',4,4',5,5'-hexaalkyl-2,2'-biphenols and 3,3',4,4',5,5',6,6'-octaalkyl-2,2'-biphenols INVISTA Technologies S.à.r.l. (CH) 2011-02-02 EP disclosed
US-20030100802-A1 Process for preparing 3,3',5,5',6,6'-hexaalkyl-2,2'-biphenols,3,3',4,4',5,5'-hexaalkyl-2,2'-biphenols and 3,3',4,4',5,5',6,6'-octaalkyl-2,2'-biphenols SHAPIRO RAFAEL (US) 2003-05-29 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030100802-A1 Process for preparing 3,3',5,5',6,6'-hexaalkyl-2,2'-biphenols,3,3',4,4',5,5'-hexaalkyl-2,2'-biphenols and 3,3',4,4',5,5',6,6'-octaalkyl-2,2'-biphenols CYP4B1, UGT1A4, CYP4X1 BCL2 1455/4885MCL1 1082/4885BCL2L1 442/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.